Impact Of Patent Expirations On The Biosimilars Market For Adalimumab, Infliximab, And Etanercept: A Significant Driver Propelling The Adalimumab, Infliximab and Etanercept Biosimilars Market In 2025

The Adalimumab, Infliximab and Etanercept Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Adalimumab, Infliximab and Etanercept Biosimilars Market Size and Projected Growth Rate?
The market size of adalimumab, infliximab, and etanercept biosimilars has seen a swift expansion in the past years. It is projected to escalate from $4.37 billion in 2024 up to $4.98 billion in 2025, with a compound annual growth rate (CAGR) of 14.1%. Factors such as increased spending on healthcare, modifications in regulation, government measures, and escalating healthcare costs have driven growth during the historic period.

The market for biosimilars of drugs like adalimumab, infliximab, and etanercept is anticipated to expand swiftly in the coming years, projected to touch $7.44 billion by 2029 with a compound annual growth rate (CAGR) of 10.5%. The escalating healthcare costs, the aging populace, and enhanced healthcare accessibility are all crucial factors propelling this growth. Throughout the forecast period, key trends would revolve around the launch of novel products, efforts towards mergers and acquisitions, establishing strategic collaborations, and boosting investment levels.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3473

What Are the Major Segments in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
The adalimumab, infliximab and etanercept biosimilars market covered in this report is segmented -

1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

Subsegments:
1) By Adalimumab Biosimilars: Amjevita (Amgen), Hyrimoz (Sandoz), Cyltezo (Boehringer Ingelheim), Others
2) By Infliximab Biosimilars: Inflectra (Pfizer), Remsima (Celltrion), Ixifi (Pfizer), Others
3) By Cipleumab: Cipleumab Biosimilars, Other Biosimilars in Development

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3473&type=smp

What Are The Driving Adalimumab, Infliximab and Etanercept Biosimilars Market Evolution?
The end of patent protections for brand-name drugs has paved the way for biosimilars to penetrate the adalimumab, infliximab, and etanercept biosimilars market. For example, in the USA, the FDA gave approval to Inflectra, a drug engineered by Hospira (owned by Pfizer Inc.), designed to treat several autoimmune afflictions including rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, following the conclusion of the patent for the branded drug Remicade. In a similar vein, the patent for Amgen's Enbrel ended in the EU, and upon this expiration, Benepali (a biosimilar to Enbrel) got the green light from the European Commission. Furthermore, after the patent for Humira expired, its biosimilars could be sold in the market. Recently, Hulio, the sixth Humira biosimilar, received FDA approval. So, the conclusion of patent protections for such branded biologic drugs like Humira, Enbrel, and Remicade is set to bolster demand in the adalimumab, infliximab, and etanercept biosimilars market.

Which Firms Dominate The Adalimumab, Infliximab and Etanercept Biosimilars Market Segments?
Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

What Trends Are Expected to Dominate the Adalimumab, Infliximab and Etanercept Biosimilars Market in the Next 5 Years?
Leading firms in the adalimumab, infliximab, and etanercept biosimilars market are concentrating their efforts on the creation of innovative products like citrate-free adalimumab, in order to offer dependable solutions to clients. This citrate-free adalimumab is a variant of the biological drug adalimumab that excludes citrate. As an example, Fresenius Kabi, a Germany-based producer of pharmaceuticals and infusion, transfusion, and clinical nutrition technologies, secured FDA approval in December 2022 for the use of biosimilar Idacio (adalimumab) in treating chronic autoimmune disorders, fitting within all approved uses of the reference product. The product has been formulated using cutting-edge analytical techniques for application in multiple chronic ailments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Which Is The Largest Region In The Adalimumab, Infliximab and Etanercept Biosimilars Market?
North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Adalimumab, Infliximab and Etanercept Biosimilars Market?
2. What is the CAGR expected in the Adalimumab, Infliximab and Etanercept Biosimilars Market?
3. What Are the Key Innovations Transforming the Adalimumab, Infliximab and Etanercept Biosimilars Industry?
4. Which Region Is Leading the Adalimumab, Infliximab and Etanercept Biosimilars Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.